MedTrace Logo

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

NCT05370885 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2025-12-17

No results posted yet for this study

Summary

A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).

Conditions

Interventions

BIOLOGICAL

VE202

VE202 is a rationally defined, live biotherapeutic product for oral administration.

DRUG

Vancomycin Oral Capsule

Vancomycin is an antibiotic used to treat or prevent infection

OTHER

VE202 Placebo

VE202 Placebo

OTHER

Vancomycin Placebo

Vancomycin Placebo

Sponsors & Collaborators

  • Vedanta Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-08
Primary Completion
2025-08-29
Completion
2025-08-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Czechia
  • Hungary
  • Lithuania
  • Netherlands
  • Poland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370885 on ClinicalTrials.gov